Aleix Prat: Reveal Genomics Announces Positive Top-line Results for HER2DX in CLEOPATRA Phase III Trial

Aleix Prat, Director of Cancer Institute and Blood Disorders at Hospital Clínic de Barcelona, shared on LinkedIn:

“REVEAL GENOMICS Announces Positive Top-line Results for HER2DX in CLEOPATRA Phase III Trial

–HER2DX was evaluated in tumor samples from 214 patients with advanced HER2+ breast cancer treated with docetaxel, trastuzumab, and pertuzumab.
–The ERBB2 mRNA levels determined by HER2DX have shown a significant association with progression-free survival (PFS) and overall survival (OS).
–HER2DX is the world’s first diagnostic test formulated specifically for HER2+ breast cancer.”

Read Further.
Source: Aleix Prat/LinkedIn